Latest Market Entry News

Urenco Limited has secured Foreign Investment Review Board approval for its strategic investment in Ubaryon, where Global Uranium and Enrichment Limited holds a significant stake, marking a key milestone in advancing innovative uranium enrichment technology.

Altech Batteries Limited has undergone a significant board and management reshuffle following a shareholder-led challenge, appointing new leadership while reaffirming its strategic focus on advanced battery technologies.

Jindalee Lithium has successfully raised $1.5 million through an oversubscribed Share Purchase Plan, exceeding its $1 million target to fund the McDermitt Lithium Project and a US SPAC transaction.

ReNerve Ltd reports a strong 53% year-on-year revenue increase, expanding its US distribution network and advancing clinical studies for its nerve repair products. The company is poised for significant global market growth with new partnerships and upcoming product launches.

Provaris Energy’s 2025 AGM highlights strategic progress in hydrogen and CO2 storage technologies, focusing on European market expansion and a refined licensing business model.

PainChek Ltd has secured FDA De Novo clearance for its Adult App, marking a pivotal entry into the US long-term care market and setting the stage for global expansion including its Infant App.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Temple & Webster Group delivered a robust FY25 with 21% revenue growth and expanded into New Zealand, reaffirming its ambitious growth and profitability targets for FY26.

Parkway Corporate Limited has marked its transition to profitability in FY25, unveiling a transformative Queensland Brine Management Complex project set to redefine waste brine processing in Australia’s coal seam gas sector.

Clarity Pharmaceuticals has raised $203 million to accelerate its copper-64 and copper-67 radiopharmaceutical pipeline, targeting prostate and neuroendocrine cancers with multiple FDA Fast Track trials underway.

HeraMED has inked a 12-month commercial agreement with Philips’ U.S. subsidiary to deliver an integrated digital maternity care platform to American hospitals, combining cutting-edge monitoring devices with HeraMED’s remote patient monitoring technology.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.